Jeremy Carlos Burns

Jeremy Carlos Burns

Auto-generated profile, based on publicly available information

Jeremy Carlos Burns

Multiple Sclerosis and Neurorepair Research Unit, Biogen, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in Immunity
Verified
Journal Article
Closed access
MJMartha S. Jordan
Martha S. Jordan
JSJennifer E. Smith
Jennifer E. Smith
JBJeremy C. Burns
Jeremy C. Burns
JAJessica-Elise T. Austin
Jessica-Elise T. Austin
KNKim E. Nichols
Kim E. Nichols
GKGary Koretzky
Gary Koretzky

24 June 2020 in eLife
Verified
Journal Article
Open access
JBJeremy Carlos Burns
Jeremy Carlos Burns
BCBunny Cotleur
Bunny Cotleur
DWDirk M Walther
Dirk M Walther
BBBekim Bajrami
Bekim Bajrami
SRStephen J Rubino
Stephen J Rubino
MMMichael Mingueneau
Michael Mingueneau
To date, microglia subsets in the healthy CNS have not been identified. Utilizing autofluorescence (AF) as a discriminating parameter, we identified two novel microglia subsets in both mice and non-human primates, termed autofluorescence-positive (AF+) and negative (AF−). While their proportion remained constant throughout most adult life, the AF signal linearly and specifically increased in AF+ microglia with age and correlated with a commensurate increase in size and complexity of lysosomal storage bodies, as detected by transmission electron microscopy and LAMP1 levels. Post-depletion repopulation kinetics revealed AF− cells as likely precursors of AF+ microglia. At the molecular level, the proteome of AF+ microglia showed overrepresentation of endolysosomal, autophagic, catabolic, and mTOR-related proteins. Mimicking the effect of advanced aging, genetic disruption of lysosomal function accelerated the accumulation of storage bodies in AF+ cells and led to impaired microglia physiology and cell death, suggestive of a mechanistic convergence between aging and lysosomal storage disorders.

16 December 2010 in Blood
Verified
Journal Article
Closed access
PDF file
JSJennifer E. Smith-Garvin
Jennifer E. Smith-Garvin
JBJeremy C. Burns
Jeremy C. Burns
MGMercy Gohil
Mercy Gohil
TZTao Zou
Tao Zou
JKJiyeon S. Kim
Jiyeon S. Kim
MJMartha S. Jordan
Martha S. Jordan
SH2 domain-containing leukocyte phosphoprotein of 76 kDa (SLP-76) nucleates a signaling complex critical for T-cell receptor (TCR) signal propagation. Mutations in the tyrosines of SLP-76 result in graded defects in TCR-induced signals depending on the tyrosine(s) affected. Here we use 2 strains of genomic knock-in mice expressing tyrosine to phenylalanine mutations to examine the role of TCR signals in the differentiation of effector and memory CD8+ T cells in response to infection in vivo. Our data support a model in which altered TCR signals can determine the rate of memory versus effector cell differentiation independent of initial T-cell expansion. Furthermore, we show that TCR signals sufficient to promote CD8+ T-cell differentiation are different from those required to elicit inflammatory cytokine production.

19 June 2021 in Brain
Verified
Journal Article
Closed access
PDF file
KPKathryn Pellerin
Kathryn Pellerin
SRStephen J Rubino
Stephen J Rubino
JBJeremy C Burns
Jeremy C Burns
BSBenjamin A Smith
Benjamin A Smith
CMChristie-Ann McCarl
Christie-Ann McCarl
MMMichael Mingueneau
Michael Mingueneau
Autoantibodies are a hallmark of numerous neurological disorders, including multiple sclerosis, autoimmune encephalitides and neuromyelitis optica. Whilst well understood in peripheral myeloid cells, the pathophysiological significance of autoantibody-induced Fc receptor signalling in microglia remains unknown, in part due to the lack of a robust in vivo model. Moreover, the application of therapeutic antibodies for neurodegenerative disease also highlights the importance of understanding Fc receptor signalling in microglia. Here, we describe a novel in vivo experimental paradigm that allows for selective engagement of Fc receptors within the CNS by peripherally injecting anti-myelin oligodendrocyte glycoprotein (MOG) monoclonal antibodies into normal wild-type mice. MOG antigen-bound immunoglobulins were detected throughout the CNS and triggered a rapid and tightly regulated proliferative response in both brain and spinal cord microglia. This microglial response was abrogated when anti-MOG antibodies were deprived of Fc receptor effector function or injected into Fcγ receptor knockout mice and was associated with the downregulation of Fc receptors in microglia, but not peripheral myeloid cells, establishing that this response was dependent on central Fc receptor engagement. Downstream of the Fc receptors, BTK was a required signalling node for this response, as microglia proliferation was amplified in BtkE41K knock-in mice expressing a constitutively active form of the enzyme and blunted in mice treated with a CNS-penetrant small molecule inhibitor of BTK. Finally, this response was associated with transient and stringently regulated changes in gene expression predominantly related to cellular proliferation, which markedly differed from transcriptional programs typically associated with Fc receptor engagement in peripheral myeloid cells. Together, these results establish a physiologically-meaningful functional response to Fc receptor and BTK signalling in microglia, while providing a novel in vivo tool to further dissect the roles of microglia-specific Fc receptor and BTK-driven responses to both pathogenic and therapeutic antibodies in CNS homeostasis and disease.

1 January 2021 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
EBEris Bame
Eris Bame
HTHao Tang
Hao Tang
JBJeremy C Burns
Jeremy C Burns
MAMillion Arefayene
Million Arefayene
KMKlaus Michelsen
Klaus Michelsen
MMMichael Mingueneau
Michael Mingueneau
Objectives: Bruton's tyrosine kinase (BTK) plays a non‐redundant signaling role downstream of the B‐cell receptor (BCR) in B cells and the receptors for the Fc region of immunoglobulins (FcR) in myeloid cells. Here, we characterise BIIB091, a novel, potent, selective and reversible small‐molecule inhibitor of BTK.Methods: BIIB091 was evaluated in vitro and in vivo in preclinical models and in phase 1 clinical trial.Results: In vitro, BIIB091 potently inhibited BTK‐dependent proximal signaling and distal functional responses in both B cells and myeloid cells with IC50s ranging from 3 to 106 nm, including antigen presentation to T cells, a key mechanism of action thought to be underlying the efficacy of B cell‐targeted therapeutics in multiple sclerosis. BIIB091 effectively sequestered tyrosine 551 in the kinase pocket by forming long‐lived complexes with BTK with t1/2 of more than 40 min, thereby preventing its phosphorylation by upstream kinases. As a key differentiating feature of BIIB091, this property explains the very potent whole blood IC50s of 87 and 106 nm observed with stimulated B cells and myeloid cells, respectively. In vivo, BIIB091 blocked B‐cell activation, antibody production and germinal center differentiation. In phase 1 healthy volunteer trial, BIIB091 inhibited naïve and unswitched memory B‐cell activation, with an in vivo IC50 of 55 nm and without significant impact on lymphoid or myeloid cell survival after 14 days of dosing.Conclusion: Pharmacodynamic results obtained in preclinical and early clinical settings support the advancement of BIIB091 in phase 2 clinical trials.

2 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Edwin Vazquez-CintronEdwin Vazquez-Cintron
Edwin Vazquez-Cintron
NMNgozi R. Monu
Ngozi R. Monu
JBJeremy C. Burns
Jeremy C. Burns
RBRoy Blum
Roy Blum
GCGregory Chen
Gregory Chen
AFAlan B. Frey
Alan B. Frey
CD8+ tumor infiltrating T cells (TIL) lack effector-phase functions due to defective proximal TCR-mediated signaling previously shown to result from inactivation of p56lck kinase. We identify a novel interacting partner for p56lck in nonlytic TIL, Protocadherin-18 (‘pcdh18’), and show that pcdh18 is transcribed upon in vitro or in vivo activation of all CD8+ central memory T cells (CD44+CD62LhiCD127+) coincident with conversion into effector memory cells (CD44+CD62LloCD127+). Expression of pcdh18 in primary CD8+ effector cells induces the phenotype of nonlytic TIL: defective proximal TCR signaling, cytokine secretion, and cytolysis, and enhanced AICD. pcdh18 contains a motif (centered at Y842) shared with src kinases (QGQYQP) that is required for the inhibitory phenotype. Thus, pcdh18 is a novel activation marker of CD8+ memory T cells that can function as an inhibitory signaling receptor and restrict the effector phase.